Clinical Trial Update: Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]

View source ↗

Summary

This article outlines a Phase 1/2 clinical trial evaluating the safety and efficacy of asciminib in pediatric and young adult patients with relapse/refractory P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abl-class Ph-like Acute Lymphoblastic Leukemia
• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Asciminib (asciminib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING